High Risk of Bias in Early COVID-19 Studies: Meta-Analysis
High Risk of Bias in Early COVID-19 Studies: Meta-Analysis
Few peer-reviewed clinical papers on the pandemic contained original data, and many of those that did had poor experimental design.
High Risk of Bias in Early COVID-19 Studies: Meta-Analysis
High Risk of Bias in Early COVID-19 Studies: Meta-Analysis

Few peer-reviewed clinical papers on the pandemic contained original data, and many of those that did had poor experimental design.

Few peer-reviewed clinical papers on the pandemic contained original data, and many of those that did had poor experimental design.

clinical trials
What’s Ahead for SARS-CoV-2 Research in 2021
What’s Ahead for SARS-CoV-2 Research in 2021
Shawna Williams | Jan 8, 2021
From new treatments to an investigation into the virus’s origins, here are some of the developments we can expect this year.
2020 in Scientists’ Own Words
2020 in Scientists’ Own Words
Abby Olena | Dec 23, 2020
The world was rocked by the COVID-19 pandemic this year, but researchers rose to all manner of challenges.
Gene Therapy in One Eye Improves Vision in Both Eyes
Gene Therapy in One Eye Improves Vision in Both Eyes
Abby Olena | Dec 11, 2020
It’s not clear why the patients with Leber hereditary optic neuropathy, a mitochondrial disorder that causes blindness, also experienced the modest benefits in their untreated eye.
<em>The Scientist</em>&#39;s LabTalk - Episode 4
The Scientist's LabTalk - Episode 4
The Scientist Creative Services Team | Dec 11, 2020
The Past, Present, and Future of Gene Therapy: How to Scale-up Successfully
RNA Interference Comes of Age
RNA Interference Comes of Age
Diana Kwon | Dec 9, 2020
The third FDA approval of an RNAi-based therapeutic marks the growing success of a technique that took two decades to get off the ground.
Opinion: Emergency Use Authorizations Are a Threat to Science<strong>&nbsp;</strong>
Opinion: Emergency Use Authorizations Are a Threat to Science 
Kevin J. Tracey, Christina Brennan | Dec 1, 2020
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
The Promise of mRNA Vaccines
The Promise of mRNA Vaccines
Diana Kwon | Nov 25, 2020
Long before Moderna’s and Pfizer’s COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.
Moderna&rsquo;s COVID-19 Vaccine 94 Percent Effective: Initial Data
Moderna’s COVID-19 Vaccine 94 Percent Effective: Initial Data
Max Kozlov | Nov 16, 2020
The results mark the second experimental COVID-19 vaccine to show high efficacy, but the study is not complete and the data have not been peer reviewed.
The MSC: Regeneration Orchestrator
The MSC: Regeneration Orchestrator
| Nov 16, 2020
Scientists uncover the promise of mesenchymal stem cells (MSCs), also known as medicinal signaling cells, to modulate the immune system and regenerate tissue.